Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

Combination treatment benefits patients with advanced breast cancer that has spread to the brain

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

The Phase II study, published today in Nature Cancer, included 17 female patients with newly diagnosed LM and HER2+ breast cancer. Median overall survival (OS) in those treated with the combination therapy increased from a historical average of 4.4 months to 10 months. At the 18-month mark, 41% of patients were still alive. Under the combination treatment, disease progression also stalled, with a median of seven months before central nervous system progression, and 7 of 12 evaluable patients also had improved neurologic deficits.

“The combination achieved a clinically meaningful improvement in overall survival compared to historical controls,” said lead author Rashmi Murthy, M.D., associate professor of Breast Medical Oncology. “For these patients, who often face limited treatment options, our results represent a step forward, offering new hope in how we treat and manage leptomeningeal metastasis.”

Glomerular basement membrane structural integrity dictates trans-tissue deposition of laminin in the kidney

Omachi and Lin et al. uncover an unexpected source of ectopic laminin-α2 deposition in the glomerular basement membrane in Alport syndrome. They show that laminin-α2 circulates in blood and deposits according to basement membrane integrity, revealing a trans-tissue route for extracellular matrix deposition in mammals.

Consequences of the Novel ALS-Associated KIF5A Variant c.2993-6C

Regulation and activation of UvrD-family DNA helicases/ translocases.

For the past few decades, the active form of superfamily 1A (SF1A) UvrDfamily helicases has been controversial due to the absence of structures of the active dimeric form of these enzymes.

A key interaction in the monomeric structures is between a regulatory domain (2B) and duplex DNA that was proposed to facilitate DNA unwinding but is likely inhibitory.

However, recent cryo-EM structures show that Mycobacterium tuberculosis UvrD1 forms a covalent dimer, with dimerization occurring between the 2B domains of each subunit, resulting in major reorientations of the 2B domains that prevent the 2B–DNA interaction, thus relieving its inhibitory effect.

The same dimerization interface is used in Escherichia coli UvrD dimers, suggesting that this is a general mechanism to activate most SF1A helicases.

Due to these insights, textbook descriptions of helicase mechanisms based on the monomeric structures require re-evaluation. sciencenewshighlights ScienceMission https://sciencemission.com/conundrum-resolved

Continue reading “Consequences of the Novel ALS-Associated KIF5A Variant c.2993-6C” | >

Defining Alzheimer’s disease: stipulations and the ethics of diagnostic change

In this really interesting essay, Michalon et al discuss defining Alzheimer’s disease in response to recent discussions on revising the definition and diagnostic criteria for the condition. The essay provides interesting historical context to the debate.

Recent revisions of Alzheimer’s Disease (AD) definitions by two leading research groups—the Alzheimer’s Association and the International Working Group—reflect divergent approaches: the former promotes a strictly biological definition, while the latter promotes a clinicalbiological construct. We contend that this emerging controversy is not merely semantic, but scientifically, clinically, and politically significant. Drawing on philosophical tools and situating the current debate within a broader historical context from the reconceptualization of AD in the 1970s onwards, we explore how definitions can serve as transformative instruments, acting as strategic bets that reshape scientific fields and clinical practices. Ultimately, we draw from the AD case study to argue for a critical reflection on the risks and promises of such definitional acts. We also propose a renewed attention to the ‘ethics of stipulating’ in the field of contemporary biomedical sciences.

In response to advances in diagnostics and therapeutics, two major research groups specialising in Alzheimer’s disease (AD) have recently revised their definition and diagnostic criteria for the condition. While they concur on certain aspects—most notably, the centrality of amyloid and tau pathologies—the two groups have proposed different types of definition. The Alzheimer’s Association (AA) group asserts the following fundamental principle: “AD is defined by its unique neuropathologic findings; therefore, detection of AD neuropathologic change by biomarkers is equivalent to diagnosing the disease” 1(p.5145). This definition regards specific biological changes as the unique defining feature rather than a joint characteristic, together with specific symptoms, of a disease. In this framework, asymptomatic individuals can be diagnosed with ‘preclinical AD’

AI rebuilds molecules from exploding fragments

Researchers at the Department of Energy’s SLAC National Accelerator Laboratory and collaborating institutions recently built a generative AI model that can recreate molecular structures from the movement of the molecule’s ions after they are blasted apart by X-rays, a technique called Coulomb explosion imaging.

The research, published in Nature Communications, is an important step toward being able to take snapshots of molecules during chemical reactions—an advance that could have important impacts in medicine and industry. The machine learning model closely predicted the geometries of a range of different molecules made of less than ten atoms, paving the way for applying the technique to larger molecules.

“We were pretty excited about this,” said Xiang Li, an associate scientist at SLAC’s Linac Coherent Light Source (LCLS) and lead author of the study. “It is the first AI model built for molecular structure reconstruction from Coulomb explosion imaging.”

Large-scale look at the exposome shows combined environmental exposures rival genetics in shaping human health outcomes

For decades, scientists have been carefully unraveling the role of genes in disease by examining how small variations in a person’s genetic code can shape lifelong risk of developing common conditions such as cancer, diabetes, or heart disease. But genetics only tell part of the story.

The other part comes from all the external and internal exposures a person experiences during their lifetime, which can range from pollution to infections to diet and lifestyle. Cumulatively, these exposures—and the body’s biological response to them—make up what scientists have termed the exposome.

A team led by scientists at Harvard Medical School has now conducted what may be the largest-scale study to date to quantify the relationships between exposures and health outcomes, testing more than 100,000 associations. The work demonstrates the importance of studying potential environmental disease risks in aggregate rather than one at a time.

Most mass spectrometers can process just a few molecules at once: Reengineered prototype does a billion simultaneously

Mass spectrometry is already a powerful tool for determining what kind and how many molecules are present in a given sample. But most instruments still analyze their molecules one or just a few at a time, an approach that is inefficient and costly, and in which rare, but significant molecules can easily fall between the cracks.

A more powerful version of the technology could one day allow scientists to read the full molecular contents of a single cell, track thousands of chemical reactions at once, and ultimately accelerate efforts like drug development.

Now, a new study describes the first big step in that direction by producing a prototype, dubbed MultiQ-IT, that’s capable of handling vast numbers of molecules at once. The findings, published in the journal Science Advances, offer a blueprint for faster, more sensitive instruments that could position mass spectrometry for the kind of transformation that reshaped genomics and computing.

Neuropsychiatric Symptoms in Patients With Pathologically Confirmed Comorbid Alzheimer Disease and Frontotemporal Lobar Degeneration

Background and ObjectivesLittle is known about the clinical presentation in patients with comorbid Alzheimer disease neuropathologic change (ADNC) and frontotemporal lobar degeneration (FTLD) neuropathology, despite frequent comorbidity of…

/* */